Advertisement
Screener

BULLFROG AI HOLDINGS, INC. (BFRG) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

BULLFROG AI HOLDINGS, INC. Operating Cash Flow

BULLFROG AI HOLDINGS, INC. (BFRG) reported Operating Cash Flow of -$3.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14

  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.51M.
  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.69M.
  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.18M.
  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.11M.
  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$5.52M.
  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$5.61M.
  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$6.00M.
  • BULLFROG AI HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$910.89K.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$1.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$3.21M
10-Q · filed 2026-08-14
-$4.39M
derived: sum of 3 quarters · filed 2026-08-14
-$5.50M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$1.69M
10-Q · filed 2026-05-14
-$2.88M
derived: sum of 2 quarters · filed 2026-05-14
-$3.99M
derived: sum of 3 quarters · filed 2026-05-14
-$5.42M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$1.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$2.29M
derived: sum of 2 quarters · filed 2026-03-19
-$3.72M
derived: sum of 3 quarters · filed 2026-08-14
-$5.52M
10-K · filed 2026-03-19
2025-09-30-$1.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
-$2.54M
derived: sum of 2 quarters · filed 2026-08-14
-$4.34M
10-Q · filed 2025-11-14
-$5.61M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$1.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$3.23M
10-Q · filed 2026-08-14
-$4.50M
derived: sum of 3 quarters · filed 2026-08-14
-$5.71M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$1.80M
10-Q · filed 2026-05-14
-$3.07M
derived: sum of 2 quarters · filed 2026-05-14
-$4.28M
derived: sum of 3 quarters · filed 2026-05-14
-$5.51M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$1.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$2.48M
derived: sum of 2 quarters · filed 2026-03-19
-$3.71M
derived: sum of 3 quarters · filed 2026-03-19
-$5.61M
10-K · filed 2026-03-19
2024-09-30-$1.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
-$2.44M
derived: sum of 2 quarters · filed 2025-11-14
-$4.34M
10-Q · filed 2025-11-14
-$5.36M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$1.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
-$3.13M
10-Q · filed 2025-08-13
-$4.15M
derived: sum of 3 quarters · filed 2025-08-13
-$5.54M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31-$1.90M
10-Q · filed 2025-05-13
-$2.92M
derived: sum of 2 quarters · filed 2025-05-13
-$4.31M
derived: sum of 3 quarters · filed 2025-05-13
-$5.54M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14
-$2.41M
derived: sum of 2 quarters · filed 2025-03-14
-$3.64M
derived: sum of 3 quarters · filed 2025-03-14
-$6.00M
10-K · filed 2025-03-14
2023-09-30-$1.39M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
-$2.62M
derived: sum of 2 quarters · filed 2024-11-08
-$4.98M
10-Q · filed 2024-11-08
-$5.02M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30-$1.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
-$3.59M
10-Q · filed 2024-08-07
-$3.63M
derived: sum of 3 quarters · filed 2024-08-07
-$3.89M
derived: sum of 4 quarters · filed 2024-08-07
2023-03-31-$2.36M
10-Q · filed 2024-05-10
-$2.40M
derived: sum of 2 quarters · filed 2024-05-10
-$2.66M
derived: sum of 3 quarters · filed 2024-05-10
-$3.26M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31-$39.65K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
-$298.88K
derived: sum of 2 quarters · filed 2024-03-29
-$901.12K
derived: sum of 3 quarters · filed 2024-03-29
-$910.89K
10-K · filed 2024-03-29
2022-09-30-$259.24K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$861.47K
derived: sum of 2 quarters · filed 2023-11-14
-$871.24K
10-Q · filed 2023-11-14
2022-06-30-$602.23K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$612.01K
10-Q · filed 2023-08-14
2022-03-31-$9.78K
10-Q · filed 2023-05-24
2021-12-31-$382.40K
10-K · filed 2023-04-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Tempest Therapeutics, Inc. (TPST)United States$0.013B